In this podcast, Sonny Goyal, chief strategy officer at Blue Cross and Blue Shield of North Carolina, discusses recent value-based initiatives to support patients and reduce overall cost of care.
Today, we bring you a podcast featuring insights from Blue Cross and Blue Shield of North Carolina. Blue Cross NC was established in 1933 and since then has been committed to serving its patient population and making health care more accessible and easy to navigate.
Sonny Goyal, chief strategy officer at Blue Cross NC, discusses some of the top priorities at Blue Cross NC, as well as the insurer’s multiple investments in primary care and the workforce to improve value-based care.
Listen above or through one of these podcast services:
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Adapting ACA Access Amid Medicaid Transition and Policy Reversals: Molly Dean
February 19th 2025As enrollment shifts to the Affordable Care Act (ACA) marketplace following the unwinding of Medicaid and the Trump administration begins to implement health policy changes, Molly Dean, MSW, Siftwell's policy advisor, shares insight on how to adapt.
Read More
“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”
February 16th 2025Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.
Read More